Preload Image
Preload Image
Report Store mobile icon
Global Anti-Depressant Market Growth 2024-2030

Global Anti-Depressant Market Growth 2024-2030

2024

Global Anti-Depressant Market Growth 2024-2030

The global Anti-Depressant market was valued at US$ 14,050 million in 2024, driven by rising mental health awareness, advancements in treatments, and increased demand for depressio

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The global anti-depressant market has experienced notable growth over the years, driven by the increasing prevalence of depression and other mood disorders worldwide. Depression is one of the leading causes of disability, affecting millions of individuals across all age groups, genders, and geographical locations. This rising burden of depression has fueled the demand for anti-depressant medications as patients and healthcare providers seek effective treatments to manage symptoms. Factors such as growing stress levels, lifestyle changes, the pressures of modern society, and the lingering mental health effects of the COVID-19 pandemic have further contributed to the heightened need for anti-depressant drugs. Alongside this, the increasing awareness and destigmatization of mental health conditions have led to more individuals seeking medical help for depression, anxiety, and related disorders, thereby driving the growth of the anti-depressant market. The development of new, more targeted antidepressant medications with fewer side effects has been a key trend in the market. Advances in pharmacology and neuroscience have led to the introduction of novel drug classes and treatment options, improving the treatment landscape for patients. As research continues to focus on improving efficacy and minimizing adverse effects, the anti-depressant market is expected to continue expanding, catering to the growing global demand for mood disorder treatments.

According to Publisher, global Anti-Depressant market size was valued at US$ 14050 million in 2024. With growing demand in downstream market, the Anti-Depressant is forecast to a readjusted size of US$ 17780 million by 2030 with a CAGR of 3.4% during review period. North America holds the largest share of the global anti-depressant market, primarily driven by the high prevalence of depression, advanced healthcare infrastructure, and widespread access to treatment. The United States, in particular, is a significant contributor to the market due to the large number of individuals diagnosed with depressive disorders and the high rates of anti-depressant prescriptions. Mental health awareness campaigns and improved healthcare access have increased the acceptance of anti-depressants as a mainstream treatment for depression and related disorders. In Europe, countries such as Germany, the United Kingdom, and France also represent significant markets, with rising demand for anti-depressant medications attributed to increasing mental health diagnoses and government efforts to improve mental health care. The Asia Pacific region, while historically underdiagnosed and undertreated in terms of mental health conditions, is now seeing rapid growth in demand for anti-depressants due to changing attitudes toward mental health and improving access to healthcare in countries like China, India, and Japan. Additionally, the increasing prevalence of mental health disorders, particularly among urban populations and youth, has led to a surge in demand for effective treatments. The market in these regions is expected to continue expanding as more individuals seek medical interventions for depression and related conditions, aided by greater mental health awareness and government support for mental health care.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample


The global anti-depressant market can be segmented by drug class, with key categories including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and atypical antidepressants. Among these, SSRIs dominate the market due to their safety profile, fewer side effects, and efficacy in treating major depressive disorder, generalized anxiety disorder, and other mood disorders. SSRIs such as fluoxetine, sertraline, and escitalopram are widely prescribed because they effectively increase serotonin levels in the brain, enhancing mood and alleviating symptoms of depression. SNRIs, which target both serotonin and norepinephrine, are also growing in popularity due to their dual action, making them effective in treating various mood and anxiety disorders. Common SNRIs include venlafaxine and duloxetine. Tricyclic antidepressants (TCAs) were once the first-line treatment for depression but have become less common due to their side effects, such as weight gain and sedation. Nevertheless, they are still used in specific cases where newer drugs are ineffective. Monoamine oxidase inhibitors (MAOIs), though effective, are generally prescribed when other medications fail, given their potential for dangerous interactions with certain foods and other medications. Atypical antidepressants, such as bupropion and mirtazapine, have gained a niche following due to their distinct mechanisms of action and potential for fewer side effects. With the ongoing advancements in psychiatric treatments and increasing focus on personalized medicine, the drug classes in the anti-depressant market are expected to evolve, catering to more specific patient needs and improving overall outcomes.

The anti-depressant market can also be segmented by application, with the key areas of treatment being major depressive disorder (MDD), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and others. Major depressive disorder remains the largest application segment, as it is one of the most common and debilitating mental health conditions globally. Antidepressants, particularly SSRIs and SNRIs, are the first-line treatments for MDD, helping patients manage symptoms such as persistent sadness, low energy, and lack of interest in daily activities. Generalized anxiety disorder, which often coexists with depression, also represents a significant portion of the market, with SSRIs and SNRIs being commonly prescribed to alleviate both anxiety and depressive symptoms. Post-traumatic stress disorder, another serious mental health condition, is treated with a variety of medications, including antidepressants that help manage the mood and emotional symptoms that often accompany PTSD. Obsessive-compulsive disorder, which involves recurring, intrusive thoughts and repetitive behaviors, is another key application area where antidepressants are used to help reduce symptoms. Additionally, antidepressants are prescribed for other conditions, such as panic disorder, social anxiety disorder, and eating disorders, further expanding the market. With increasing recognition of the importance of mental health care and the broadening range of applications for antidepressant treatments, the market is expected to grow and evolve, with innovations in drug development providing more targeted and effective treatment options for patients. As the global understanding of mental health continues to improve, the demand for antidepressants is expected to rise, fueling the market's growth in the coming years.


Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Sikandar Kesari

Research Analyst



Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Sikandar Kesari

Table of Contents

  • 1 Scope of the Report
  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered
  • 1.8 Market Estimation Caveats
  • 2 Executive Summary
  • 2.1 World Market Overview
  • 2.1.1 Global Anti-Depressant Annual Sales 2019-2030
  • 2.1.2 World Current & Future Analysis for Anti-Depressant by Geographic Region, 2019, 2023 & 2030
  • 2.1.3 World Current & Future Analysis for Anti-Depressant by Country/Region, 2019, 2023 & 2030
  • 2.2 Anti-Depressant Segment by Type
  • 2.2.1 Tricyclic Antidepressants
  • 2.2.2 Selective Serotonin Reuptake Inhibitors
  • 2.2.3 Serotonin-Norepinephrine Reuptake Inhibitors
  • 2.2.4 Monoamine Oxidase Inhibitors
  • 2.2.5 Serotonin Antagonist
  • 2.2.6 Reuptake Inhibitors
  • 2.2.7 Others
  • 2.3 Anti-Depressant Sales by Type
  • 2.3.1 Global Anti-Depressant Sales Market Share by Type (2019-2024)
  • 2.3.2 Global Anti-Depressant Revenue and Market Share by Type (2019-2024)
  • 2.3.3 Global Anti-Depressant Sale Price by Type (2019-2024)
  • 2.4 Anti-Depressant Segment by Application
  • 2.4.1 Major Depressive Disorder
  • 2.4.2 Obsessive-Compulsive Disorder
  • 2.4.3 Generalized Anxiety Disorder
  • 2.4.4 Panic Disorder
  • 2.4.5 Others
  • 2.5 Anti-Depressant Sales by Application
  • 2.5.1 Global Anti-Depressant Sale Market Share by Application (2019-2024)
  • 2.5.2 Global Anti-Depressant Revenue and Market Share by Application (2019-2024)
  • 2.5.3 Global Anti-Depressant Sale Price by Application (2019-2024)
  • 3 Global Anti-Depressant by Company
  • 3.1 Global Anti-Depressant Breakdown Data by Company
  • 3.1.1 Global Anti-Depressant Annual Sales by Company (2019-2024)
  • 3.1.2 Global Anti-Depressant Sales Market Share by Company (2019-2024)
  • 3.2 Global Anti-Depressant Annual Revenue by Company (2019-2024)
  • 3.2.1 Global Anti-Depressant Revenue by Company (2019-2024)
  • 3.2.2 Global Anti-Depressant Revenue Market Share by Company (2019-2024)
  • 3.3 Global Anti-Depressant Sale Price by Company
  • 3.4 Key Manufacturers Anti-Depressant Producing Area Distribution, Sales Area, Product Type
  • 3.4.1 Key Manufacturers Anti-Depressant Product Location Distribution
  • 3.4.2 Players Anti-Depressant Products Offered
  • 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Anti-Depressant by Geographic Region
  • 4.1 World Historic Anti-Depressant Market Size by Geographic Region (2019-2024)
  • 4.1.1 Global Anti-Depressant Annual Sales by Geographic Region (2019-2024)
  • 4.1.2 Global Anti-Depressant Annual Revenue by Geographic Region (2019-2024)
  • 4.2 World Historic Anti-Depressant Market Size by Country/Region (2019-2024)
  • 4.2.1 Global Anti-Depressant Annual Sales by Country/Region (2019-2024)
  • 4.2.2 Global Anti-Depressant Annual Revenue by Country/Region (2019-2024)
  • 4.3 Americas Anti-Depressant Sales Growth
  • 4.4 APAC Anti-Depressant Sales Growth
  • 4.5 Europe Anti-Depressant Sales Growth
  • 4.6 Middle East & Africa Anti-Depressant Sales Growth
  • 5 Americas
  • 5.1 Americas Anti-Depressant Sales by Country
  • 5.1.1 Americas Anti-Depressant Sales by Country (2019-2024)
  • 5.1.2 Americas Anti-Depressant Revenue by Country (2019-2024)
  • 5.2 Americas Anti-Depressant Sales by Type
  • 5.3 Americas Anti-Depressant Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil
  • 6 APAC
  • 6.1 APAC Anti-Depressant Sales by Region
  • 6.1.1 APAC Anti-Depressant Sales by Region (2019-2024)
  • 6.1.2 APAC Anti-Depressant Revenue by Region (2019-2024)
  • 6.2 APAC Anti-Depressant Sales by Type
  • 6.3 APAC Anti-Depressant Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan
  • 7 Europe
  • 7.1 Europe Anti-Depressant by Country
  • 7.1.1 Europe Anti-Depressant Sales by Country (2019-2024)
  • 7.1.2 Europe Anti-Depressant Revenue by Country (2019-2024)
  • 7.2 Europe Anti-Depressant Sales by Type
  • 7.3 Europe Anti-Depressant Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia
  • 8 Middle East & Africa
  • 8.1 Middle East & Africa Anti-Depressant by Country
  • 8.1.1 Middle East & Africa Anti-Depressant Sales by Country (2019-2024)
  • 8.1.2 Middle East & Africa Anti-Depressant Revenue by Country (2019-2024)
  • 8.2 Middle East & Africa Anti-Depressant Sales by Type
  • 8.3 Middle East & Africa Anti-Depressant Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends
  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis
  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Anti-Depressant
  • 10.3 Manufacturing Process Analysis of Anti-Depressant
  • 10.4 Industry Chain Structure of Anti-Depressant
  • 11 Marketing, Distributors and Customer
  • 11.1 Sales Channel
  • 11.1.1 Direct Channels
  • 11.1.2 Indirect Channels
  • 11.2 Anti-Depressant Distributors
  • 11.3 Anti-Depressant Customer
  • 12 World Forecast Review for Anti-Depressant by Geographic Region
  • 12.1 Global Anti-Depressant Market Size Forecast by Region
  • 12.1.1 Global Anti-Depressant Forecast by Region (2025-2030)
  • 12.1.2 Global Anti-Depressant Annual Revenue Forecast by Region (2025-2030)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Anti-Depressant Forecast by Type
  • 12.7 Global Anti-Depressant Forecast by Application
  • 13 Key Players Analysis
  • 13.1 Alkermes
  • 13.1.1 Alkermes Company Information
  • 13.1.2 Alkermes Anti-Depressant Product Portfolios and Specifications
  • 13.1.3 Alkermes Anti-Depressant Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.1.4 Alkermes Main Business Overview
  • 13.1.5 Alkermes Latest Developments
  • 13.2 Allergan
  • 13.2.1 Allergan Company Information
  • 13.2.2 Allergan Anti-Depressant Product Portfolios and Specifications
  • 13.2.3 Allergan Anti-Depressant Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.2.4 Allergan Main Business Overview
  • 13.2.5 Allergan Latest Developments
  • 13.3 Bristol-Myers Squibb
  • 13.3.1 Bristol-Myers Squibb Company Information
  • 13.3.2 Bristol-Myers Squibb Anti-Depressant Product Portfolios and Specifications
  • 13.3.3 Bristol-Myers Squibb Anti-Depressant Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.3.4 Bristol-Myers Squibb Main Business Overview
  • 13.3.5 Bristol-Myers Squibb Latest Developments
  • 13.4 Eli Lilly and Company
  • 13.4.1 Eli Lilly and Company Company Information
  • 13.4.2 Eli Lilly and Company Anti-Depressant Product Portfolios and Specifications
  • 13.4.3 Eli Lilly and Company Anti-Depressant Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.4.4 Eli Lilly and Company Main Business Overview
  • 13.4.5 Eli Lilly and Company Latest Developments
  • 13.5 GlaxoSmithKline
  • 13.5.1 GlaxoSmithKline Company Information
  • 13.5.2 GlaxoSmithKline Anti-Depressant Product Portfolios and Specifications
  • 13.5.3 GlaxoSmithKline Anti-Depressant Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.5.4 GlaxoSmithKline Main Business Overview
  • 13.5.5 GlaxoSmithKline Latest Developments
  • 13.6 Lundbeck
  • 13.6.1 Lundbeck Company Information
  • 13.6.2 Lundbeck Anti-Depressant Product Portfolios and Specifications
  • 13.6.3 Lundbeck Anti-Depressant Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.6.4 Lundbeck Main Business Overview
  • 13.6.5 Lundbeck Latest Developments
  • 13.7 Merck
  • 13.7.1 Merck Company Information
  • 13.7.2 Merck Anti-Depressant Product Portfolios and Specifications
  • 13.7.3 Merck Anti-Depressant Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.7.4 Merck Main Business Overview
  • 13.7.5 Merck Latest Developments
  • 13.8 Pfizer
  • 13.8.1 Pfizer Company Information
  • 13.8.2 Pfizer Anti-Depressant Product Portfolios and Specifications
  • 13.8.3 Pfizer Anti-Depressant Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.8.4 Pfizer Main Business Overview
  • 13.8.5 Pfizer Latest Developments
  • 13.9 Teva Pharmaceutical Industries
  • 13.9.1 Teva Pharmaceutical Industries Company Information
  • 13.9.2 Teva Pharmaceutical Industries Anti-Depressant Product Portfolios and Specifications
  • 13.9.3 Teva Pharmaceutical Industries Anti-Depressant Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.9.4 Teva Pharmaceutical Industries Main Business Overview
  • 13.9.5 Teva Pharmaceutical Industries Latest Developments
  • 13.10 Takeda Pharmaceutical
  • 13.10.1 Takeda Pharmaceutical Company Information
  • 13.10.2 Takeda Pharmaceutical Anti-Depressant Product Portfolios and Specifications
  • 13.10.3 Takeda Pharmaceutical Anti-Depressant Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.10.4 Takeda Pharmaceutical Main Business Overview
  • 13.10.5 Takeda Pharmaceutical Latest Developments
  • 14 Research Findings and Conclusion


Table 1. Anti-Depressant Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Anti-Depressant Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Tricyclic Antidepressants
Table 4. Major Players of Selective Serotonin Reuptake Inhibitors
Table 5. Major Players of Serotonin-Norepinephrine Reuptake Inhibitors
Table 6. Major Players of Monoamine Oxidase Inhibitors
Table 7. Major Players of Serotonin Antagonist
Table 8. Major Players of Reuptake Inhibitors
Table 9. Major Players of Others
Table 10. Global Anti-Depressant Sales by Type (2019-2024) & (K Units)
Table 11. Global Anti-Depressant Sales Market Share by Type (2019-2024)
Table 12. Global Anti-Depressant Revenue by Type (2019-2024) & ($ million)
Table 13. Global Anti-Depressant Revenue Market Share by Type (2019-2024)
Table 14. Global Anti-Depressant Sale Price by Type (2019-2024) & (USD/Unit)
Table 15. Global Anti-Depressant Sales by Application (2019-2024) & (K Units)
Table 16. Global Anti-Depressant Sales Market Share by Application (2019-2024)
Table 17. Global Anti-Depressant Revenue by Application (2019-2024)
Table 18. Global Anti-Depressant Revenue Market Share by Application (2019-2024)
Table 19. Global Anti-Depressant Sale Price by Application (2019-2024) & (USD/Unit)
Table 20. Global Anti-Depressant Sales by Company (2019-2024) & (K Units)
Table 21. Global Anti-Depressant Sales Market Share by Company (2019-2024)
Table 22. Global Anti-Depressant Revenue by Company (2019-2024) ($ Millions)
Table 23. Global Anti-Depressant Revenue Market Share by Company (2019-2024)
Table 24. Global Anti-Depressant Sale Price by Company (2019-2024) & (USD/Unit)
Table 25. Key Manufacturers Anti-Depressant Producing Area Distribution and Sales Area
Table 26. Players Anti-Depressant Products Offered
Table 27. Anti-Depressant Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 28. New Products and Potential Entrants
Table 29. Mergers & Acquisitions, Expansion
Table 30. Global Anti-Depressant Sales by Geographic Region (2019-2024) & (K Units)
Table 31. Global Anti-Depressant Sales Market Share Geographic Region (2019-2024)
Table 32. Global Anti-Depressant Revenue by Geographic Region (2019-2024) & ($ millions)
Table 33. Global Anti-Depressant Revenue Market Share by Geographic Region (2019-2024)
Table 34. Global Anti-Depressant Sales by Country/Region (2019-2024) & (K Units)
Table 35. Global Anti-Depressant Sales Market Share by Country/Region (2019-2024)
Table 36. Global Anti-Depressant Revenue by Country/Region (2019-2024) & ($ millions)
Table 37. Global Anti-Depressant Revenue Market Share by Country/Region (2019-2024)
Table 38. Americas Anti-Depressant Sales by Country (2019-2024) & (K Units)
Table 39. Americas Anti-Depressant Sales Market Share by Country (2019-2024)
Table 40. Americas Anti-Depressant Revenue by Country (2019-2024) & ($ Millions)
Table 41. Americas Anti-Depressant Revenue Market Share by Country (2019-2024)
Table 42. Americas Anti-Depressant Sales by Type (2019-2024) & (K Units)
Table 43. Americas Anti-Depressant Sales by Application (2019-2024) & (K Units)
Table 44. APAC Anti-Depressant Sales by Region (2019-2024) & (K Units)
Table 45. APAC Anti-Depressant Sales Market Share by Region (2019-2024)
Table 46. APAC Anti-Depressant Revenue by Region (2019-2024) & ($ Millions)
Table 47. APAC Anti-Depressant Revenue Market Share by Region (2019-2024)
Table 48. APAC Anti-Depressant Sales by Type (2019-2024) & (K Units)
Table 49. APAC Anti-Depressant Sales by Application (2019-2024) & (K Units)
Table 50. Europe Anti-Depressant Sales by Country (2019-2024) & (K Units)
Table 51. Europe Anti-Depressant Sales Market Share by Country (2019-2024)
Table 52. Europe Anti-Depressant Revenue by Country (2019-2024) & ($ Millions)
Table 53. Europe Anti-Depressant Revenue Market Share by Country (2019-2024)
Table 54. Europe Anti-Depressant Sales by Type (2019-2024) & (K Units)
Table 55. Europe Anti-Depressant Sales by Application (2019-2024) & (K Units)
Table 56. Middle East & Africa Anti-Depressant Sales by Country (2019-2024) & (K Units)
Table 57. Middle East & Africa Anti-Depressant Sales Market Share by Country (2019-2024)
Table 58. Middle East & Africa Anti-Depressant Revenue by Country (2019-2024) & ($ Millions)
Table 59. Middle East & Africa Anti-Depressant Revenue Market Share by Country (2019-2024)
Table 60. Middle East & Africa Anti-Depressant Sales by Type (2019-2024) & (K Units)
Table 61. Middle East & Africa Anti-Depressant Sales by Application (2019-2024) & (K Units)
Table 62. Key Market Drivers & Growth Opportunities of Anti-Depressant
Table 63. Key Market Challenges & Risks of Anti-Depressant
Table 64. Key Industry Trends of Anti-Depressant
Table 65. Anti-Depressant Raw Material
Table 66. Key Suppliers of Raw Materials
Table 67. Anti-Depressant Distributors List
Table 68. Anti-Depressant Customer List
Table 69. Global Anti-Depressant Sales Forecast by Region (2025-2030) & (K Units)
Table 70. Global Anti-Depressant Revenue Forecast by Region (2025-2030) & ($ millions)
Table 71. Americas Anti-Depressant Sales Forecast by Country (2025-2030) & (K Units)
Table 72. Americas Anti-Depressant Revenue Forecast by Country (2025-2030) & ($ millions)
Table 73. APAC Anti-Depressant Sales Forecast by Region (2025-2030) & (K Units)
Table 74. APAC Anti-Depressant Revenue Forecast by Region (2025-2030) & ($ millions)
Table 75. Europe Anti-Depressant Sales Forecast by Country (2025-2030) & (K Units)
Table 76. Europe Anti-Depressant Revenue Forecast by Country (2025-2030) & ($ millions)
Table 77. Middle East & Africa Anti-Depressant Sales Forecast by Country (2025-2030) & (K Units)
Table 78. Middle East & Africa Anti-Depressant Revenue Forecast by Country (2025-2030) & ($ millions)
Table 79. Global Anti-Depressant Sales Forecast by Type (2025-2030) & (K Units)
Table 80. Global Anti-Depressant Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 81. Global Anti-Depressant Sales Forecast by Application (2025-2030) & (K Units)
Table 82. Global Anti-Depressant Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 83. Alkermes Basic Information, Anti-Depressant Manufacturing Base, Sales Area and Its Competitors
Table 84. Alkermes Anti-Depressant Product Portfolios and Specifications
Table 85. Alkermes Anti-Depressant Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 86. Alkermes Main Business
Table 87. Alkermes Latest Developments
Table 88. Allergan Basic Information, Anti-Depressant Manufacturing Base, Sales Area and Its Competitors
Table 89. Allergan Anti-Depressant Product Portfolios and Specifications
Table 90. Allergan Anti-Depressant Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 91. Allergan Main Business
Table 92. Allergan Latest Developments
Table 93. Bristol-Myers Squibb Basic Information, Anti-Depressant Manufacturing Base, Sales Area and Its Competitors
Table 94. Bristol-Myers Squibb Anti-Depressant Product Portfolios and Specifications
Table 95. Bristol-Myers Squibb Anti-Depressant Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 96. Bristol-Myers Squibb Main Business
Table 97. Bristol-Myers Squibb Latest Developments
Table 98. Eli Lilly and Company Basic Information, Anti-Depressant Manufacturing Base, Sales Area and Its Competitors
Table 99. Eli Lilly and Company Anti-Depressant Product Portfolios and Specifications
Table 100. Eli Lilly and Company Anti-Depressant Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 101. Eli Lilly and Company Main Business
Table 102. Eli Lilly and Company Latest Developments
Table 103. GlaxoSmithKline Basic Information, Anti-Depressant Manufacturing Base, Sales Area and Its Competitors
Table 104. GlaxoSmithKline Anti-Depressant Product Portfolios and Specifications
Table 105. GlaxoSmithKline Anti-Depressant Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 106. GlaxoSmithKline Main Business
Table 107. GlaxoSmithKline Latest Developments
Table 108. Lundbeck Basic Information, Anti-Depressant Manufacturing Base, Sales Area and Its Competitors
Table 109. Lundbeck Anti-Depressant Product Portfolios and Specifications
Table 110. Lundbeck Anti-Depressant Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 111. Lundbeck Main Business
Table 112. Lundbeck Latest Developments
Table 113. Merck Basic Information, Anti-Depressant Manufacturing Base, Sales Area and Its Competitors
Table 114. Merck Anti-Depressant Product Portfolios and Specifications
Table 115. Merck Anti-Depressant Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 116. Merck Main Business
Table 117. Merck Latest Developments
Table 118. Pfizer Basic Information, Anti-Depressant Manufacturing Base, Sales Area and Its Competitors
Table 119. Pfizer Anti-Depressant Product Portfolios and Specifications
Table 120. Pfizer Anti-Depressant Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 121. Pfizer Main Business
Table 122. Pfizer Latest Developments
Table 123. Teva Pharmaceutical Industries Basic Information, Anti-Depressant Manufacturing Base, Sales Area and Its Competitors
Table 124. Teva Pharmaceutical Industries Anti-Depressant Product Portfolios and Specifications
Table 125. Teva Pharmaceutical Industries Anti-Depressant Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 126. Teva Pharmaceutical Industries Main Business
Table 127. Teva Pharmaceutical Industries Latest Developments
Table 128. Takeda Pharmaceutical Basic Information, Anti-Depressant Manufacturing Base, Sales Area and Its Competitors
Table 129. Takeda Pharmaceutical Anti-Depressant Product Portfolios and Specifications
Table 130. Takeda Pharmaceutical Anti-Depressant Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 131. Takeda Pharmaceutical Main Business
Table 132. Takeda Pharmaceutical Latest Developments
List of


Figure 1. Picture of Anti-Depressant
Figure 2. Anti-Depressant Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-Depressant Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Anti-Depressant Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Anti-Depressant Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Tricyclic Antidepressants
Figure 10. Product Picture of Selective Serotonin Reuptake Inhibitors
Figure 11. Product Picture of Serotonin-Norepinephrine Reuptake Inhibitors
Figure 12. Product Picture of Monoamine Oxidase Inhibitors
Figure 13. Product Picture of Serotonin Antagonist
Figure 14. Product Picture of Reuptake Inhibitors
Figure 15. Product Picture of Others
Figure 16. Global Anti-Depressant Sales Market Share by Type in 2023
Figure 17. Global Anti-Depressant Revenue Market Share by Type (2019-2024)
Figure 18. Anti-Depressant Consumed in Major Depressive Disorder
Figure 19. Global Anti-Depressant Market: Major Depressive Disorder (2019-2024) & (K Units)
Figure 20. Anti-Depressant Consumed in Obsessive-Compulsive Disorder
Figure 21. Global Anti-Depressant Market: Obsessive-Compulsive Disorder (2019-2024) & (K Units)
Figure 22. Anti-Depressant Consumed in Generalized Anxiety Disorder
Figure 23. Global Anti-Depressant Market: Generalized Anxiety Disorder (2019-2024) & (K Units)
Figure 24. Anti-Depressant Consumed in Panic Disorder
Figure 25. Global Anti-Depressant Market: Panic Disorder (2019-2024) & (K Units)
Figure 26. Anti-Depressant Consumed in Others
Figure 27. Global Anti-Depressant Market: Others (2019-2024) & (K Units)
Figure 28. Global Anti-Depressant Sales Market Share by Application (2023)
Figure 29. Global Anti-Depressant Revenue Market Share by Application in 2023
Figure 30. Anti-Depressant Sales Market by Company in 2023 (K Units)
Figure 31. Global Anti-Depressant Sales Market Share by Company in 2023
Figure 32. Anti-Depressant Revenue Market by Company in 2023 ($ Million)
Figure 33. Global Anti-Depressant Revenue Market Share by Company in 2023
Figure 34. Global Anti-Depressant Sales Market Share by Geographic Region (2019-2024)
Figure 35. Global Anti-Depressant Revenue Market Share by Geographic Region in 2023
Figure 36. Americas Anti-Depressant Sales 2019-2024 (K Units)
Figure 37. Americas Anti-Depressant Revenue 2019-2024 ($ Millions)
Figure 38. APAC Anti-Depressant Sales 2019-2024 (K Units)
Figure 39. APAC Anti-Depressant Revenue 2019-2024 ($ Millions)
Figure 40. Europe Anti-Depressant Sales 2019-2024 (K Units)
Figure 41. Europe Anti-Depressant Revenue 2019-2024 ($ Millions)
Figure 42. Middle East & Africa Anti-Depressant Sales 2019-2024 (K Units)
Figure 43. Middle East & Africa Anti-Depressant Revenue 2019-2024 ($ Millions)
Figure 44. Americas Anti-Depressant Sales Market Share by Country in 2023
Figure 45. Americas Anti-Depressant Revenue Market Share by Country in 2023
Figure 46. Americas Anti-Depressant Sales Market Share by Type (2019-2024)
Figure 47. Americas Anti-Depressant Sales Market Share by Application (2019-2024)
Figure 48. United States Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 49. Canada Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 50. Mexico Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 51. Brazil Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 52. APAC Anti-Depressant Sales Market Share by Region in 2023
Figure 53. APAC Anti-Depressant Revenue Market Share by Regions in 2023
Figure 54. APAC Anti-Depressant Sales Market Share by Type (2019-2024)
Figure 55. APAC Anti-Depressant Sales Market Share by Application (2019-2024)
Figure 56. China Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 57. Japan Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 58. South Korea Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 59. Southeast Asia Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 60. India Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 61. Australia Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 62. China Taiwan Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 63. Europe Anti-Depressant Sales Market Share by Country in 2023
Figure 64. Europe Anti-Depressant Revenue Market Share by Country in 2023
Figure 65. Europe Anti-Depressant Sales Market Share by Type (2019-2024)
Figure 66. Europe Anti-Depressant Sales Market Share by Application (2019-2024)
Figure 67. Germany Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 68. France Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 69. UK Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 70. Italy Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 71. Russia Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 72. Middle East & Africa Anti-Depressant Sales Market Share by Country in 2023
Figure 73. Middle East & Africa Anti-Depressant Revenue Market Share by Country in 2023
Figure 74. Middle East & Africa Anti-Depressant Sales Market Share by Type (2019-2024)
Figure 75. Middle East & Africa Anti-Depressant Sales Market Share by Application (2019-2024)
Figure 76. Egypt Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 77. South Africa Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 78. Israel Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 79. Turkey Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 80. GCC Country Anti-Depressant Revenue Growth 2019-2024 ($ Millions)
Figure 81. Manufacturing Cost Structure Analysis of Anti-Depressant in 2023
Figure 82. Manufacturing Process Analysis of Anti-Depressant
Figure 83. Industry Chain Structure of Anti-Depressant
Figure 84. Channels of Distribution
Figure 85. Global Anti-Depressant Sales Market Forecast by Region (2025-2030)
Figure 86. Global Anti-Depressant Revenue Market Share Forecast by Region (2025-2030)
Figure 87. Global Anti-Depressant Sales Market Share Forecast by Type (2025-2030)
Figure 88. Global Anti-Depressant Revenue Market Share Forecast by Type (2025-2030)
Figure 89. Global Anti-Depressant Sales Market Share Forecast by Application (2025-2030)
Figure 90. Global Anti-Depressant Revenue Market Share Forecast by Application (2025-2030)

Related Tags

Related Reports

payment cards

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted

Quick Contacts

Want to customize this report?

We offer 10% Free Customization at the time of purchase

Get Free Customization

I'm Available

Kavita Mehra

Kavita Mehra

Business Development Manager

Trusted Partners

NONWOVENS_INDUSTRY
FB
issuewire
Financial_Express
logo_yourstory
FB

Budget constraints? Get in touch with us for special pricing

Request Discount

Order Detail

  • Order Placed (09 May, 2026)
  • Notify To Team (09 May, 2026)
  • Report updation (10 May, 2026)
  • Report Quality Check (10 May, 2026)
  • Report Dispatch (11 May, 2026)

  • paypal
  • icici
  • stripe
  • wire-transfer

  • Email
  • Hard Copy

Research Methodology

An Adaptive Approach to Modern-day Research Needs

Get Methodology

Recently Viewed Products

Logo

Global Anti-Depressant Market Growth 2024-2030

ChatGPT Summarize Gemini Summarize Perplexity AI Summarize Grok AI Summarize Copilot Summarize

Contact usWe are friendly and approachable, give us a call.

We uses Cookies

We use cookies to ensure you get the best experience on our website.